Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan  

作　　者：Abhijit Shete Aheson Shaikh K Javeed Nayeem Lily Rodrigues Mohamed Sheikamunadeen Sadiq Ali Parag Shah Rajiv Khanna Sarfaraj Majid Sabeer A Rasheed Shehla Shaikh Tawfiqur Rahman 

机构地区：[1]Medical Department,Novartis Pharma AG,CH-4002 Basel,Switzerland [2]Diabetes Care Centre [3]Bibi Ayesha Mili Hospital [4]Suraksha Multi Speciality Hospital [5]Irfan Cardiac and Diabetic Clinic [6]Gujarat Endocrine Centre [7]Khanna Clinic,Gole Darwaza,Radhey lal,Chowk,Lucknow 226003,India [8]B P Poddar Hospital [9]Dr.Rasheed’s Diabetes Speciality Centre [10]KGN Diabetes & Endocrinology Center [11]GD Diabetic Institute

出　　处：《World Journal of Diabetes》2013年第6期358-364,共7页世界糖尿病杂志（英文版）（电子版）

基　　金：Supported by Novartis Healthcare Private Limited,India

摘　　要：AIM:To compare the use of vildagliptin and sulfonylurea with or without metformin in Indian Muslim patients with type 2 diabetes mellitus,fasting during Ramadan.METHODS:This was a 4-wk,multicenter,non-interventional,open-label,observational study.Incidence of hypoglycemic events(HEs),adverse events,and changes in glycosylated hemoglobin A1c(HbA1c),fasting plasma glucose,postprandial plasma glucose and body weight were measured pre-and post-Ramadan.RESULTS:Totally,97 patients were recruited and all completed the study(vildagliptin group,n=55;sulfonylurea group,n=42).HEs were reported in low frequencies in both the vildagliptin and the sulfonylurea groups[0 vs 2(4.8%)patients,respectively].Interestingly,HbA1c reduced by-0.43%(-4.71 mmol/mol)in the vildagliptin group[8.75%(72.10 mmol/mol)to8.32%(67.38 mmol/mol),P=0.009]while in the sulfonylurea group there was a small increase by 0.01%[0.08 mmol/mol;8.64%(70.92 mmol/mol)to 8.65%(71.00 mmol/mol),P=0.958].Higher percentage of vildagliptin-treated patients achieved HbA1c<7.0%(<53 mmol/mol)compared with sulfonylurea(16.4%vs4.8%).Mean decrease in the body weight was 1.2 kg and 0.03 kg,respectively(P<0.001).Both treatment groups were well tolerated during Ramadan.CONCLUSION:Vildagliptin is an attractive treatment option for Indian patients with type 2 diabetes mellitus who are fasting during Ramadan.AIM:To compare the use of vildagliptin and sulfonylurea with or without metformin in Indian Muslim patients with type 2 diabetes mellitus,fasting during Ramadan.METHODS:This was a 4-wk,multicenter,non-interventional,open-label,observational study.Incidence of hypoglycemic events(HEs),adverse events,and changes in glycosylated hemoglobin A1c(HbA1c),fasting plasma glucose,postprandial plasma glucose and body weight were measured pre-and post-Ramadan.RESULTS:Totally,97 patients were recruited and all completed the study(vildagliptin group,n=55;sulfonylurea group,n=42).HEs were reported in low frequencies in both the vildagliptin and the sulfonylurea groups[0 vs 2(4.8%)patients,respectively].Interestingly,HbA1c reduced by-0.43%(-4.71 mmol/mol)in the vildagliptin group[8.75%(72.10 mmol/mol)to8.32%(67.38 mmol/mol),P=0.009]while in the sulfonylurea group there was a small increase by 0.01%[0.08 mmol/mol;8.64%(70.92 mmol/mol)to 8.65%(71.00 mmol/mol),P=0.958].Higher percentage of vildagliptin-treated patients achieved HbA1c&lt;7.0%(&lt;53 mmol/mol)compared with sulfonylurea(16.4%vs4.8%).Mean decrease in the body weight was 1.2 kg and 0.03 kg,respectively(P&lt;0.001).Both treatment groups were well tolerated during Ramadan.CONCLUSION:Vildagliptin is an attractive treatment option for Indian patients with type 2 diabetes mellitus who are fasting during Ramadan.

关 键 词：Dipeptidyl-peptidase 4 inhibitors FASTING hypoglycemia SULFONYLUREA Type 2 DIABETES mellitus VILDAGLIPTIN 

分 类 号：R587.1[医药卫生—内分泌]